Clinical Trials
23 trialsNCT03409614 2026-05-18
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT07477808 2026-03-23
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 3 Not yet recruiting
NCT03774732 2026-02-25
NIRVANA-LUNG
UNICANCER
Phase 3 Active not recruiting
NCT06899126 2026-01-08
DESTINY-Lung06
Daiichi Sankyo
Phase 3 Recruiting
NCT07135882 2025-08-22
PRIME-Lung
Trans Tasman Radiation Oncology Group
Phase 3 Not yet recruiting
NCT07016126 2025-06-11
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
Phase 3 Recruiting
NCT06598527 2025-05-29
SACTION2401
Sun Yat-sen University
Phase 3 Recruiting
NCT06828757 2025-02-19
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 3 Not yet recruiting
NCT04866017 2024-10-31
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
NCT00030771 2024-01-17
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
Swiss Cancer Institute
Phase 3 Completed
NCT05157776 2023-05-09
A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations
Tongji University
Phase 3 Unknown
NCT02448797 2021-07-20
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT04951648 2021-07-07
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03417037 2018-04-30
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02883543 2016-08-30
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3 Unknown
NCT00003387 2016-07-20
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT01342965 2015-02-24
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Hoffmann-La Roche
Phase 3 Completed
NCT00535275 2015-02-16
NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy
Intergroupe Francophone de Cancerologie Thoracique
Phase 3 Terminated
NCT00039039 2013-12-18
Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00864331 2013-08-07
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
International Atomic Energy Agency
Phase 3 Completed
NCT00042302 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated
NCT00042315 2012-05-23
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
QLT Inc.
Phase 3 Terminated